New Strategies to Detect Cancers in Carriers of Mutations in RB1

Plain-language summary

This study examines new strategies for early detection of cancers in people who carry mutations in the RB1 gene, using blood samples. It enrolled people with a germline RB1 mutation as well as a control group without it (adults and children with retinoblastoma). The study was a non-phased study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Amsterdam UMC, location VUmc

Intervention

blood draw

Start date

12/13/2018

Estimated completion

3/31/2023

Countries

France, Germany, Netherlands

Related genes

Locations

• Paris, France
• Essen, Germany
• Amsterdam, Netherlands

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Adult (16 years and older):

* Group 1: germline mutation RB1.
* Group 2 (control): no germline mutation RB1.

Pediatric (until 6 years of age):

* Group 1: somatic or germline mutation RB1 and retinoblastoma.
* Group 2 (control): no mutation RB1.

Exclusion Criteria:

Adult (16 years and older):

* Group 1: concomitant heritable (inherited) disorder other than caused by monoallelic mutation of RB1.
* Group 2 (control): cancer or already known cancer predisposition syndrome.

Pediatric (until 6 years of age):

* Group 1: concomitant heritable (inherited) disorder other than caused by monoallelic mutation of RB1.
* Group 2: cancer or already known cancer predisposition syndrome.